Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18926907 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | October 2024 | February 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 18916471 | METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICS | October 2024 | April 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18743946 | (E)-1-(2-(4-SUBSTITUTEDPHENYL)-2-OXOETHYL)-4-((HYDROXYIMINO)METHYL)PYRIDINIUM BROMIDES AS ANTITUBERCULAR AGENTS | June 2024 | September 2024 | Allow | 3 | 0 | 0 | No | No |
| 18676249 | NICORANDIL DERIVATIVES | May 2024 | June 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18668653 | STABLE PHARMACEUTICAL COMPOSITION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG DERIVATIVE | May 2024 | June 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18642051 | In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors | April 2024 | May 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18696857 | VANIN-1 INHIBITOR | March 2024 | June 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18620393 | COMPOSITIONS CONTAINING PARAXANTHINE AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | March 2024 | July 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18595919 | USE OF THYROID BETA-AGONISTS | March 2024 | July 2025 | Allow | 16 | 1 | 1 | No | No |
| 18587006 | METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS | February 2024 | July 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18423201 | 4-[4,4-BIS(4-CHLOROPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | January 2024 | August 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18393556 | METHODS FOR INHIBITING FASCIN | December 2023 | April 2025 | Allow | 16 | 0 | 1 | No | No |
| 18520091 | METHOD OF TREATING A PERSON AFFLICTED WITH A RESPIRATORY CONDITION AND PHARMACEUTICAL FORMULATION INCLUDING DAPSONE | November 2023 | April 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18508830 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | November 2023 | April 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18389167 | EMULSION FORMULATIONS | November 2023 | March 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18501814 | IMMEDIATE AND CONTROLLED RELEASE APPETITE SUPPRESSANT COMPOSITIONS FOR WEIGHT LOSS | November 2023 | February 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18386017 | (E)-1-(2-(4-SUBSTITUTEDPHENYL)-2-OXOETHYL)-4-((HYDROXYIMINO)METHYL)PYRIDINIUM BROMIDES AS ANTITUBERCULAR AGENTS | November 2023 | October 2024 | Abandon | 12 | 1 | 1 | No | No |
| 18494441 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES OR DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | October 2023 | June 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18491311 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | October 2023 | June 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18491301 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | October 2023 | May 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18491319 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | October 2023 | June 2024 | Allow | 8 | 1 | 0 | No | No |
| 18491291 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | October 2023 | April 2024 | Allow | 6 | 1 | 0 | No | No |
| 18484564 | LIQUID NIMODIPINE COMPOSITIONS | October 2023 | April 2025 | Allow | 18 | 1 | 0 | No | No |
| 18483780 | THERAPEUTIC USES OF 1-[2-(2,4-DIMETHYL-PHENYLSULFANYL)PHENYL]PIPERAZINE | October 2023 | April 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18244168 | NON-AQUEOUS LIQUID NIMODIPINE COMPOSITIONS | September 2023 | September 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18446268 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | August 2023 | February 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18355802 | METHOD OF VIRAL INHIBITION | July 2023 | August 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18218372 | Levodopa Fatty Acid Derivatives, Formulations Thereof, and Their Uses for the Treatment of Parkinson's Disease | July 2023 | March 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18207893 | INTELLIGENT DELIVERY OF INGESTED AND ABSORBED MOLECULES | June 2023 | March 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18331688 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS | June 2023 | May 2025 | Allow | 23 | 1 | 0 | Yes | No |
| 18319220 | APPLICATION OF PYRROLE-2-CARBOXALDEHYDE IN CONTROLLING PLANT ROOT-KNOT NEMATODES | May 2023 | June 2024 | Abandon | 13 | 1 | 1 | No | No |
| 18312466 | STABLE PHARMACEUTICAL COMPOSITION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG DERIVATIVE | May 2023 | December 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18182125 | COMPOSITIONS CONTAINING PARAXANTHINE AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | March 2023 | March 2024 | Allow | 12 | 3 | 0 | Yes | No |
| 18180064 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | March 2023 | September 2024 | Abandon | 18 | 2 | 1 | No | No |
| 18176860 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | March 2023 | July 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18176816 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | March 2023 | July 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18176855 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | March 2023 | July 2023 | Allow | 5 | 0 | 0 | Yes | No |
| 18175142 | FOOD SUPPLEMENT AND COMPOSITION COMPRISING CHOLINE BUTYRATE SALT AND/OR BUTYRYLCHOLINE | February 2023 | December 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 18114305 | METHOD AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF BROAD SPECTRUM VIRUS AILMENTS COMPRISING A CALCIUM CHANNEL BLOCKER OR A CALMODULIN BLOCKER | February 2023 | December 2024 | Abandon | 22 | 0 | 1 | No | No |
| 18175123 | FOOD SUPPLEMENT AND COMPOSITION COMPRISING CHOLINE BUTYRATE SALT AND/OR BUTYRYLCHOLINE | February 2023 | March 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18171254 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | February 2023 | May 2025 | Abandon | 27 | 3 | 1 | No | No |
| 18102136 | MODULATION OF SOLUBILITY, STABILITY, ABSORPTION, METABOLISM, AND PHARMACOKINETIC PROFILE OF LIPOPHILIC DRUGS BY STEROLS | January 2023 | January 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18152399 | SLEEP DISORDER TREATMENT AND PREVENTION | January 2023 | August 2024 | Allow | 19 | 1 | 0 | No | No |
| 18148682 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | December 2022 | June 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18090547 | SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB | December 2022 | October 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 18088756 | METHODS AND AGENTS THAT ENHANCE MYOGENIC PROGENITOR CELL ENGRAFTMENT | December 2022 | May 2024 | Allow | 17 | 0 | 1 | Yes | No |
| 18068403 | TREATMENT OF HERPES ZOSTER WITH TOPICAL TETRACAINE | December 2022 | July 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18081390 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | December 2022 | July 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18062911 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | December 2022 | August 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18076044 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | December 2022 | July 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17993216 | Treatment Of Adipocytes | November 2022 | April 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 17974027 | LIQUID NIMODIPINE COMPOSITIONS | October 2022 | July 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 17974032 | LIQUID NIMODIPINE COMPOSITIONS | October 2022 | July 2023 | Allow | 8 | 1 | 0 | No | No |
| 17920611 | Use of Salmeterol as an Anti-Coronaviral Agent | October 2022 | April 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18046492 | DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST | October 2022 | September 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17955337 | METHOD OF TREATING A PERSON AFFLICTED WITH COVID-19 AND PHARMACEUTICAL FORMULATION INCLUDING DAPSONE | September 2022 | July 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 17907470 | KETONE ESTER AS A THERAPEUTIC TREATMENT OF COVID -19 AND RELATED VIRAL INFECTIONS | September 2022 | May 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17947789 | COMPOSITIONS AND METHODS FOR TREATING AN INFECTION | September 2022 | February 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 17932982 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | September 2022 | June 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 17903372 | THERAPEUTIC USE OF COMPOUNDS | September 2022 | May 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 17901896 | HIGH CONCENTRATION MEDICANT SOLUTIONS FOR TREATING NEUROLOGICAL DISORDERS | September 2022 | August 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17908686 | ISOPAUCIFLORAL F PHOSPHATE COMPOUND AND PHARMACEUTICAL USE THEREOF | September 2022 | May 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17898196 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | August 2022 | May 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17820025 | METHOD OF IMPROVING SLEEP | August 2022 | June 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17885460 | NICORANDIL DERIVATIVES | August 2022 | March 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17873592 | METHOD FOR CONTROLLING GROWTH OF MICROORGANISMS AND/OR BIOFILMS IN AN INDUSTRIAL PROCESS | July 2022 | May 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17861844 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | July 2022 | August 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 17857958 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERTENSION | July 2022 | March 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 17847760 | SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB | June 2022 | January 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 17847734 | SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB | June 2022 | January 2023 | Allow | 6 | 1 | 0 | No | No |
| 17807487 | TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE | June 2022 | April 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17842374 | Use of Ibezapolstat to Promote Microbiome Health | June 2022 | May 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17834367 | (3AR)-1,3A,8-TRIMETHYL-1 ,2,3,3A,8,8AHEXAHYDROPYRROLO[2,3-B]INDOL-5-YL PHENYLCARBAMATE AND METHODS OF TREATING OR PREVENTING NEURODEGENERATION | June 2022 | July 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17830374 | ANTIMICROBIAL COMPOSITION | June 2022 | July 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17750716 | COMPOSITIONS AND METHODS TO REGULATE HORMONAL CASCADES IN STRESS DISORDERS | May 2022 | July 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17662494 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS | May 2022 | July 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17738181 | COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF TREATING OR PREVENTING HEMATOLOGIC DISORDERS, AND/OR RELATED DISEASES | May 2022 | April 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 17738621 | USE OF THYROID BETA-AGONISTS | May 2022 | December 2023 | Allow | 19 | 1 | 0 | No | No |
| 17733690 | APPETITE SUPPRESSANT COMPOSITIONS AND METHODS THEREOF | April 2022 | November 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17711561 | ADMINISTRATION OF BUTYRATE, BETA-HYDROXYBUTYRATE, CANNABIDIOL, AND RELATED COMPOUNDS IN HUMANS | April 2022 | August 2024 | Allow | 28 | 2 | 0 | Yes | No |
| 17708669 | LIQUID NIMODIPINE COMPOSITIONS | March 2022 | October 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17702315 | SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB | March 2022 | January 2025 | Abandon | 34 | 2 | 1 | Yes | No |
| 17680591 | METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICS | February 2022 | August 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17678579 | Preservatives for Cosmetic, Toiletry and Pharmaceutical Compositions | February 2022 | December 2024 | Abandon | 34 | 1 | 1 | Yes | No |
| 17676032 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | February 2022 | January 2023 | Abandon | 11 | 1 | 0 | Yes | No |
| 17676017 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | February 2022 | January 2023 | Abandon | 11 | 1 | 0 | Yes | No |
| 17672592 | TREATMENT OF AUTISM AND AUTISM SPECTRUM DISORDERS WITH BIOTIN COMPOSITIONS | February 2022 | March 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17650417 | MULTIFUNCTIONAL NATURAL PROTECTANT SYSTEMS WITH HYDROXYACETOPHENONE | February 2022 | February 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17665894 | METHOD FOR THE TREATMENT OF COVID-19 INFECTIONS WITH PALMITOYLETHANOLAMIDE | February 2022 | March 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17665806 | METHOD AND COMPOUND FOR THE TREATMENT OF COVID-19 | February 2022 | July 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17590796 | Compositions And Kits Useful For Treatment Of Respiratory Illness | February 2022 | September 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17589281 | NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES | January 2022 | August 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17570584 | APPLICATION OF ACTIVE INGREDIENT WGX50 IN ZANTHOXYLUM BUNGEANUM EXTRACT | January 2022 | August 2023 | Abandon | 19 | 1 | 1 | Yes | No |
| 17570998 | THERAPEUTIC USES OF 1-[2-(2,4-DIMETHYL-PHENYLSULFANYL)PHENYL]PIPERAZINE | January 2022 | November 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17558919 | Non-Aqueous Liquid Nimodipine Compositions | December 2021 | May 2022 | Abandon | 5 | 1 | 0 | No | No |
| 17558924 | NON-AQUEOUS LIQUID NIMODIPINE COMPOSITIONS | December 2021 | June 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17554842 | Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions | December 2021 | August 2024 | Allow | 32 | 2 | 0 | Yes | No |
| 17618871 | TRIPLE PHARMACEUTICAL COMPOSITION FOR PROTEINACEOUS INFECTION | December 2021 | April 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17549828 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | December 2021 | January 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17643751 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | December 2021 | December 2023 | Allow | 24 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAMACHANDRAN, UMAMAHESWARI.
With a 8.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RAMACHANDRAN, UMAMAHESWARI works in Art Unit 1627 and has examined 1,175 patent applications in our dataset. With an allowance rate of 53.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner RAMACHANDRAN, UMAMAHESWARI's allowance rate of 53.1% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RAMACHANDRAN, UMAMAHESWARI receive 1.77 office actions before reaching final disposition. This places the examiner in the 53% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by RAMACHANDRAN, UMAMAHESWARI is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +56.5% benefit to allowance rate for applications examined by RAMACHANDRAN, UMAMAHESWARI. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.5% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 34.7% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 66.2% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 61.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 49.8% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.4% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.6% of allowed cases (in the 51% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.